Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)

Suspended
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2019

At a glance

  • Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone; Topotecan
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TAHOE
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Dec 2018 According to an AbbVie media release, the Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrolment to be stopped in this trial due to shorter overall survival in the Rova-T arm compared with the topotecan control arm. The IDMC recommended that investigators and patients make individual decisions as to whether or not to continue treatment based on patient level response.
    • 05 Dec 2018 Status changed from recruiting to suspended, according to an AbbVie media release.
    • 10 Oct 2018 Planned End Date changed from 31 Jul 2020 to 30 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top